Merck KGaA (FRA:MRK) Given Average Rating of “Hold” by Brokerages

Merck KGaA (FRA:MRK) has earned a consensus rating of “Hold” from the nineteen ratings firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, thirteen have given a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is €101.33 ($117.83).

MRK has been the subject of several research analyst reports. Warburg Research set a €103.00 ($119.77) target price on Merck KGaA and gave the stock a “neutral” rating in a research report on Tuesday, July 30th. UBS Group set a €99.00 ($115.12) target price on Merck KGaA and gave the stock a “neutral” rating in a research report on Thursday, August 8th. Sanford C. Bernstein set a €114.00 ($132.56) target price on Merck KGaA and gave the stock a “neutral” rating in a research report on Wednesday, October 9th. JPMorgan Chase & Co. set a €100.00 ($116.28) target price on Merck KGaA and gave the stock a “neutral” rating in a research report on Thursday, September 12th. Finally, Deutsche Bank set a €96.00 ($111.63) target price on Merck KGaA and gave the stock a “neutral” rating in a research report on Friday, August 9th.

Shares of FRA:MRK traded up €0.25 ($0.29) on Monday, hitting €104.15 ($121.10). 221,418 shares of the company’s stock were exchanged. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72). The business’s 50 day simple moving average is €100.05 and its two-hundred day simple moving average is €95.64.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. It offers prescription medicines to treat cancer, multiple sclerosis, infertility, growth deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, as well as squamous cell carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Featured Story: What are the Different Types of Leveraged Buyouts?

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.